{
  "events": [
    {
      "drug": "ORLADEYO (berotralstat)",
      "indication": "Hereditary angioedema (HAE)",
      "company": "BioCryst Pharmaceuticals Inc",
      "pdufa_date": "2025-09-12",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "Atebimetinib + mGnP",
      "indication": "in First-Line Pancreatic Cancer Patients",
      "company": "Immuneering Corporation",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-09-25",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "Aficamten",
      "indication": "Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)",
      "company": "Cytokinetics Inc",
      "pdufa_date": "2025-09-26",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "Tolebrutinib",
      "indication": "Bruton\u2019s tyrosine kinase (BTK) inhibitor",
      "company": "Sanofi SA",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-09-28",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    }
  ]
}